Anselme L Perrier
Overview
Explore the profile of Anselme L Perrier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Louca M, El Akrouti D, Lemesle A, Louessard M, Dufour N, Baroin C, et al.
Neurobiol Dis
. 2024 Oct;
202:106703.
PMID: 39482152
No abstract available.
2.
Parmar M, Perrier A
Handb Clin Neurol
. 2024 Sep;
205:3-14.
PMID: 39341661
Regenerative medicine is an emerging and rapidly evolving field of research and therapeutics aimed to restore, maintain, and improve body functions. In the adult mammalian brain, very few neurons, if...
3.
Louca M, El Akrouti D, Lemesle A, Louessard M, Dufour N, Baroin C, et al.
Neurobiol Dis
. 2024 Aug;
200:106630.
PMID: 39106928
Despite growing descriptions of wild-type Huntingtin (wt-HTT) roles in both adult brain function and, more recently, development, several clinical trials are exploring HTT-lowering approaches that target both wt-HTT and the...
4.
Louessard M, Cailleret M, Jarrige M, Bigarreau J, Lenoir S, Dufour N, et al.
J Huntingtons Dis
. 2024 Mar;
13(1):41-53.
PMID: 38427495
Background: Mutations in the Huntingtin (HTT) gene cause Huntington's disease (HD), a neurodegenerative disorder. As a scaffold protein, HTT is involved in numerous cellular functions, but its normal and pathogenic...
5.
Duarte F, Vachey G, Caron N, Sipion M, Rey M, Perrier A, et al.
Hum Gene Ther
. 2023 Sep;
34(17-18):958-974.
PMID: 37658843
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a toxic gain-of-function CAG expansion in the first exon of the huntingtin () gene. The monogenic nature of HD makes...
6.
Gribaudo S, Bousset L, Courte J, Melki R, Peyrin J, Perrier A
Methods Mol Biol
. 2022 Oct;
2551:357-378.
PMID: 36310215
Aggregated alpha-synuclein (α-Syn) in neurons is a hallmark of Parkinson's disease (PD) and other synucleinopathies. Recent advances (1) in the production and purification of synthetic assemblies of α-Syn, (2) in...
7.
Rosser A, Busse M, Gray W, Badin R, Perrier A, Wheelock V, et al.
Brain
. 2022 Mar;
145(5):1584-1597.
PMID: 35262656
There has been substantial progress in the development of regenerative medicine strategies for CNS disorders over the last decade, with progression to early clinical studies for some conditions. However, there...
8.
Bigarreau J, Rouach N, Perrier A, Mouthon F, Charveriat M
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163606
Generation of relevant and robust models for neurological disorders is of main importance for both target identification and drug discovery. The non-cell autonomous effects of glial cells on neurons have...
9.
Virlogeux A, Scaramuzzino C, Lenoir S, Carpentier R, Louessard M, Genoux A, et al.
Sci Adv
. 2021 Apr;
7(14).
PMID: 33789888
Huntington disease (HD) damages the corticostriatal circuitry in large part by impairing transport of brain-derived neurotrophic factor (BDNF). We hypothesized that improving vesicular transport of BDNF could slow or prevent...
10.
Rosser A, Busse M, Badin R, Canals J, Wheelock V, Perrier A, et al.
Mov Disord
. 2021 Mar;
36(3):787-788.
PMID: 33749919
No abstract available.